Prolonged Response of a Patient with Relapsed Acute Myeloid Leukemia to a Novel Oral Bromodomain Extraterminal Inhibitor (BETi)
Acute myeloid leukemia (AML) is an aggressive clonal bone marrow cancer characterized by high rates of relapse and mortality. A middle-aged woman with AML relapsed twice after achieving complete remission with induction therapy and subsequent salvage therapy. She was then enrolled in a clinical tria...
Saved in:
| Main Authors: | Meilen Chang Muñoz, Jennifer A. Murphy, Johannes E. Wolff, Brian A. Jonas |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2020/8830123 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota
by: Min Wang, et al.
Published: (2025-02-01) -
The Inhibition of Bromodomain and Extraterminal Domain (BET) Proteins Protects Against Microglia-Mediated Neuronal Loss In Vitro
by: Marta Matuszewska, et al.
Published: (2025-04-01) -
Corrigendum to “The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota” [Volume 10, Issue 2, February 2025, Pages 522-534]
by: Min Wang, et al.
Published: (2025-05-01) -
The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia
by: Yesid Alvarado-Valero, et al.
Published: (2025-08-01) -
A Minireview on BET Inhibitors: Beyond Bromodomain Targeting
by: Mikhail S. Iudin, et al.
Published: (2025-03-01)